Who owns CytomX Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CTMX from SEC Form 13F filings across 178 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 178 institutions disclosed 213.0M shares of CytomX Therapeutics, Inc. worth $799.0M — about 97.3% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
178
13F holders
$799.0M
value, 2026 filers
97.3%
of shares outstanding (213.0M sh)
46
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of CTMX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 32.7M | $122.7M | 0.0% | 14.9% | +2.4% |
| 2 | Kynam Capital Management, LP | 21.7M | $81.4M | 4.5% | 9.9% | +44.6% |
| 3 | BlackRock, Inc. | 17.6M | $65.8M | 0.0% | 8% | +235.9% |
| 4 | BANK OF AMERICA CORP /DE/ | 15.1M | $56.6M | 0.0% | 6.9% | +47.8% |
| 5 | STATE STREET CORP | 11.7M | $44.1M | 0.0% | 5.4% | +107.4% |
| 6 | PERCEPTIVE ADVISORS LLC | 10.4M | $39.1M | 0.6% | 4.8% | +3.4% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 8.5M | $32.0M | 0.0% | 3.9% | -2.4% |
| 8 | Point72 Asset Management, L.P. | 7.8M | $29.3M | 0.0% | 3.6% | -0.8% |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 5.2M | $19.4M | 0.0% | 2.4% | +44.3% |
| 10 | Venrock Adviser, LLC | 5.0M | $18.7M | 0.6% | 2.3% | -50.1% |
| 11 | BAKER BROS. ADVISORS LP | 5.0M | $18.7M | 0.1% | 2.3% | 0.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 4.7M | $17.5M | 0.0% | 2.1% | +126.4% |
| 13 | Elmind Capital, LP | 4.5M | $17.1M | 4.3% | 2.1% | 0.0% |
| 14 | Nextech Invest Ltd. | 4.4M | $16.7M | 0.8% | 2% | 0.0% |
| 15 | TWO SIGMA INVESTMENTS, LP | 4.1M | $15.5M | 0.0% | 1.9% | +52.5% |
| 16 | Eversept Partners, LP | 3.6M | $13.3M | 0.7% | 1.6% | +11.6% |
| 17 | UBS Group AG | 3.5M | $13.0M | 0.0% | 1.6% | +11.2% |
| 18 | Siren, L.L.C. | 3.5M | $13.0M | 0.3% | 1.6% | 0.0% |
| 19 | ADAR1 Capital Management, LLC | 3.4M | $12.6M | 0.6% | 1.5% | -1.3% |
| 20 | CITADEL ADVISORS LLC | 3.1M | $11.7M | 0.0% | 1.4% | -42.5% |
| 21 | MARSHALL WACE, LLP | 3.0M | $11.3M | 0.0% | 1.4% | -26.9% |
| 22 | Woodline Partners LP | 2.0M | $7.7M | 0.0% | 0.9% | +2.0% |
| 23 | GOLDMAN SACHS GROUP INC | 2.0M | $7.5M | 0.0% | 0.9% | +37.3% |
| 24 | DIMENSIONAL FUND ADVISORS LP | 1.9M | $7.0M | 0.0% | 0.8% | -3.7% |
| 25 | Qube Research & Technologies Ltd | 1.8M | $6.8M | 0.0% | 0.8% | -18.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.